|1.||Oberlies, Nicholas H: 5 articles (02/2013 - 05/2005)|
|2.||Agarwal, Rajesh: 4 articles (02/2013 - 05/2005)|
|3.||Graf, Tyler N: 3 articles (02/2013 - 05/2005)|
|4.||Kroll, David J: 3 articles (02/2013 - 05/2005)|
|5.||Hawke, Roy L: 3 articles (12/2011 - 09/2008)|
|6.||Schrieber, Sarah J: 3 articles (12/2011 - 09/2008)|
|7.||Fried, Michael W: 3 articles (12/2011 - 09/2008)|
|8.||Smith, Philip C: 3 articles (12/2011 - 09/2008)|
|9.||Wen, Zhiming: 3 articles (12/2011 - 09/2008)|
|10.||Polyak, Stephen J: 2 articles (02/2013 - 06/2010)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/15/2005 - "Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells."
05/15/2005 - "Whereas several other more abundant flavonolignans do ultimately influence the same end points at higher exposure concentrations, these findings are suggestive that extracts enriched for isosilybin B, or isosilybin B alone, might possess improved potency in prostate cancer prevention and treatment."
01/01/2012 - "Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling."
07/01/2007 - "Silymarin and, one of its constituents, silibinin exert strong efficacy against prostate cancer (PCA); however, anticancer efficacy and associated mechanisms of other components of silymarin, which is a mixture of flavonolignans, are largely unknown. "
|2.||Skin Neoplasms (Skin Cancer)
03/11/2015 - "Flavonolignans and other constituents from Lepidium meyenii with activities in anti-inflammation and human cancer cell lines."
02/01/2011 - "In contrast, the radical-scavenging and antioxidant properties of silibinin and other flavonolignans in milk thistle extract may have contributed to the decrease in background tumors in rodents in the present studies. "
06/01/2008 - "The active extract of milk thistle, silymarin, is a mixture of flavonolignans and is a strong antioxidant that has been proved to promote liver cell regeneration, to reduce blood cholesterol and to help prevent cancer. "
01/01/2015 - "Most of non-taxifolin derived flavonolignans have been shown to exhibit in vitro and/or in vivo anti-hepatotoxic, anti-oxidant, free radical scavenging, anti-inflammatory, anti-proliferative, anti-cancer, chemotherapy potentiating, anti-melanogenic, anti-bacterial, vasorelaxing, anti-platelet aggregation and/or hypotriglyceridemic activity, often stronger than silybin. "
02/01/2013 - "Flavonolignans from milk thistle (Silybum marianum) have been investigated for their cellular modulatory properties, including cancer chemoprevention and hepatoprotection, as an extract (silymarin), as partially purified mixtures (silibinin and isosilibinin), and as pure compounds (a series of seven isomers). "
|4.||Liver Diseases (Liver Disease)
09/01/2008 - "The aim of this study was to determine the pharmacokinetics of the major silymarin flavonolignans in liver disease patients. "
09/01/2008 - "Silymarin, used by 30 to 40% of liver disease patients, is composed of six major flavonolignans, each of which may contribute to silymarin's hepatoprotective properties. "
01/01/1998 - "Silymarin, a mixture of flavonolignans from medicinal plant Silybum marianum, is used in supportive treatment of liver diseases of different etiology due to its hepatoprotective activity, which is considered to involve antioxidative and the membrane stabilizing effects. "
12/01/2011 - "The single- and multiple-dose pharmacokinetics of silymarin flavonolignans were examined in patients with nonalcoholic fatty liver disease (NAFLD) or hepatitis C virus (HCV) to determine whether the disposition of silymarin and therefore its potential efficacy vary among liver disease populations. "
12/01/2011 - "Silymarin, derived from the milk thistle plant Silybum marianum and widely used for self-treatment of liver diseases, is composed of six major flavonolignans including silybin A and silybin B, which are the predominant flavonolignans quantified in human plasma. "
05/01/2015 - "The present study investigated the effect of silibinin, the principal potential anti-inflammatory flavonoid contained in silymarin, a mixture of flavonolignans extracted from Silybum marianum seeds, on palmitate-induced insulin resistance in C2C12 myotubes and its potential molecular mechanisms. "
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Non-alcoholic Fatty Liver Disease
|7.||Caspase 3 (Caspase-3)
|8.||Telomerase (Telomerase Reverse Transcriptase)
|9.||Biological Markers (Surrogate Marker)
|10.||nestin (nestin protein)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)